https://www.fiercebiotech.com/biotech/jpm24-roches-pharma-bd-chief-explains-renewed-adc-interest-and-invisible-bar-all-dealmaking?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=9706A0310367J1T
The text below is an excerpt from the article above. Don't we have the part highlighted done and dusted
In October, Roche penned a deal potentially worth $216 million with SpliceBio for a gene therapy against an inherited retinal disease, which is Spark’s sweet spot thanks to FDA-approved Luxturna.The gene therapy world just celebrated a major breakthrough with the approval of Vertex and CRISPR Therapeutics’ Casgevy, the first gene-editing therapy based on CRISPR technology. Still, Sabry argued that the main limitation for gene therapy is the lack of ability to target specific cells effectively.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
0.040(3.33%) |
Mkt cap ! $723.2M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.24 | $1.19 | $1.500M | 1.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 204320 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 4333 | 2 |
View Market Depth
| Last trade - 16.11pm 24/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |